# A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients

> **NCT01513850** · PHASE3 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 87 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Hepabulin IV

## Key facts

- **NCT ID:** NCT01513850
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2015-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513850, "A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01513850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*